The future of medicine
“Ethically and scientifically, there is no going back,” proclaimed the Personalized Medicine Coalition in last year’s annual report. And indeed, we have observed a tremendous development of stratified medicine in the last years. In 2014, 20% of FDA’s novel new drug approvals were personalized medicines.
We would like to invite you to the 6th Munich Biomarker Conference to witness how personalized medicine improves health outcomes already today. Recent advances in immunotherapy and combination therapies will be presented. As every year, the meeting highlights latest examples of biomarker discovery, validation and clinical use as well as strategies for biomarker-driven drug development. It will showcase exciting technology developments pushing the boundaries of what is feasible.
Munich is one of Europe’s leading biotech locations with a strategic focus on personalized medicine. BioM, the networking organization for biotechnology in Munich and Bavaria, is organizing the international conference in its sixth year. With the aim to accelerate biomedical innovation, we bring together international experts from biotech and pharma industry with academic scientists and physicians.
Call for Abstracts
The 6th Munich Biomarker Conference planning committee welcomes your abstracts for oral presentations or for scientific posters.
Submit an abstract (see right column) and share your expertise in:
- Biomarker Discovery, Validation and Clinical Use
- Biomarkers in Drug Discovery and Development
- Innovative Biomarker Technologies, Cell-Based and Cell-Free Assays, Liquid Biopsy
- Biomarkers for Immunotherapy
- Personalized Medicine, Companion Diagnostics and Patient Selection
- Combination Therapies, Patient Monitoring, Evidence-Based Medicine